8-K: Alumis and ACELYRIN Reaffirm Commitment to All-Stock Merger, Aiming to Create Biopharma Leader

Alumis and ACELYRIN have reaffirmed their commitment to merge in an all-stock transaction, with the goal of creating a leading clinical-stage biopharmaceutical company focused on immune-mediated diseases.

Summary

• Alumis Inc. and ACELYRIN, INC. have reaffirmed their commitment to merge in an all-stock transaction.
• The merger aims to create a leading clinical stage biopharma company in immune-mediated diseases.
• The combined company is expected to have a stronger financial position and a diverse pipeline.
• The combined company had approximately $737 million in cash, cash equivalents, and marketable securities on a pro forma basis as of December 31, 2024.
• This cash position is expected to fund the company's pipeline through multiple key data readouts and cover operating expenses into 2027.
• The transaction is expected to close in the second quarter of 2025, pending stockholder approval and customary closing conditions.
• Alumis expects to file the S-4 and begin mailing the proxy statement promptly following completion of the fiscal year 2024 audits and filing of Annual Reports on Form 10-K by each of Alumis and ACELYRIN.

Sentiment

Score: 8

Explanation: The document conveys a positive outlook regarding the merger, highlighting the potential for value creation and a strong financial position. The reaffirmation of commitment suggests confidence in the deal's success.

Positives

• The merger is expected to create a leading clinical-stage biopharma company.
• The combined company will have a stronger financial position with approximately $737 million in cash as of December 31, 2024.
• The increased financial flexibility and runway will advance an expanded late-stage pipeline and build commercial capabilities.
• The combined company will have a diversified portfolio of late-stage clinical assets for validated targets.
• The merger is expected to unlock value for current and future investors.

Risks

• The proposed transaction may not be completed in a timely manner or at all.
• Required approvals, including stockholder approvals, may not be received.
• The announcement or pendency of the transaction may negatively impact Alumis' and ACELYRIN's ability to retain key personnel and maintain relationships.
• The transaction may divert management's attention from ongoing business operations.
• Legal proceedings related to the transaction could arise.
• The anticipated benefits and synergies of the merger may not be fully realized or may take longer to realize than expected.
• There are risks relating to the value of Alumis securities to be issued in the proposed transaction.
• Integration of the proposed transaction post-closing may not occur as anticipated.

Future Outlook

The combined company expects its cash position to provide runway through multiple planned key data readouts across several clinical trials and to fund operating expenses and capital expenditure requirements into 2027.

Management Comments

• Martin Babler, President, Chief Executive Officer and Chairman of Alumis, said, Alumis and ACELYRIN together will advance exciting breakthroughs for patients and drive long-term value for stockholders through the creation of a leading clinical stage biopharma company in immune-mediated diseases.
• Mina Kim, Chief Executive Officer of ACELYRIN, stated that the all-stock transaction with Alumis maximizes long-term value for ACELYRIN stockholders and continues to recommend that stockholders support the planned merger.

Industry Context

The merger reflects a trend in the biopharmaceutical industry towards consolidation to strengthen pipelines, reduce costs, and increase the likelihood of successful drug development and commercialization, particularly in the competitive field of immune-mediated diseases.

Comparison to Industry Standards

• The combined cash position of $737 million is significant and provides a competitive advantage compared to other clinical-stage biopharma companies.
• For example, comparable companies like Annexon Biosciences and Kyverna Therapeutics, also focused on immune-mediated diseases, have raised significant capital through IPOs and follow-on offerings to fund their clinical programs.
• The merger allows the combined company to compete more effectively with larger, established players in the immunology space, such as AbbVie and Bristol Myers Squibb, which have extensive resources and diverse product portfolios.

Stakeholder Impact

• Shareholders are expected to benefit from the potential value accretion of the combined company.
• Patients may benefit from the development of life-changing medicines.
• Employees of both companies may experience changes as a result of the merger.

Next Steps

• Alumis expects to publicly file the S-4 and begin mailing of the proxy statement related to the transaction promptly following completion of the fiscal year 2024 audits and filing of Annual Reports on Form 10-K by each of Alumis and ACELYRIN.
• Stockholders of both companies need to approve the transaction.
• Customary closing conditions need to be satisfied.
• Alumis and ACELYRIN will file an investor presentation with the Securities and Exchange Commission with background information regarding ACELYRINs strategic review process, which will be available this week.

Key Dates